Market Cap 2.12B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 18,172,518
Avg Vol 7,423,978
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 86%
Beta 1.20
Analysts Strong Sell
Price Target $10.75

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
raccoonblackbear
raccoonblackbear Aug. 11 at 10:35 PM
$ABCL loving these new bears who just came out of the woods and decided that crossing highways would be their new hobby. No one is a fan of the timing of the offering, but this will effectively shut anyone up who says ABCL will run out of cash before the completion of Phase 3. 2 steps backwards... 100 steps forward. My guess is the offering will be about a 10% discount from the time of the announcement... So $8.50-$9.00 becomes the new rock solid floor after the short attack. Let the bears think they have this one. Congrats longs. Y'all know who you are.
0 · Reply
PattyBergeron
PattyBergeron Aug. 11 at 10:33 PM
$ABCL im unphased. Smart business planning to preserve capital to advance the program. Offering announced but still flat on the day at the end of it.
0 · Reply
Titosimox
Titosimox Aug. 11 at 10:31 PM
$ABCL I am always astounded by the number of comments from would-be short-term traders who haven't grasped the first thing about investing and managing a company's growth. While fools stare at dung flies, investors gaze at the stars—and remain patient.
0 · Reply
PolarBear1
PolarBear1 Aug. 11 at 10:29 PM
$ABCL My guess is it’s already way oversubscribed (at or within 10% of market) and they take more than $200MM. Baker Brothers takes at least 33% (pre-funded warrants is one of their signatures) and one of the brothers (likely Felix) joins the Board post Issue. That would be fantastic news indeed. Then they’ll announce a major pharma development/marketing partnership for 635 just prior to JP Morgam Healthcare conference in SFO in mid January 2027. $15-$20 ps by then if so.
0 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 11 at 10:28 PM
$ABCL perspective: $200M for a $3B company
0 · Reply
SnoddyTradz
SnoddyTradz Aug. 11 at 10:22 PM
$ABCL If you’re still holding at this point! Stop Trading!🤣
0 · Reply
topstockalerts
topstockalerts Aug. 11 at 10:16 PM
AbCellera Biologics shares declined in after-hours trading Tuesday after the clinical-stage biotech announced a proposed $200M underwritten public offering of common stock. For certain investors, the company may offer pre-funded warrants to purchase common shares instead. All securities in the offering will be issued and sold by AbCellera. The company expects to use the net proceeds primarily to support continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635. Funds will also be used for working capital and other general corporate purposes, providing additional liquidity as AbCellera advances its drug candidates through clinical development. The proposed offering remains subject to market and other customary conditions, and AbCellera said there is no assurance that it will be completed, when it will close, or what its final size and terms will be. $ABCL
0 · Reply
SnoddyTradz
SnoddyTradz Aug. 11 at 10:11 PM
$ABCL This is so Cooked tomorrow! Stick a fork in it! It’s Done! 6.00 tomorrow!
1 · Reply
tradersunion353
tradersunion353 Aug. 11 at 10:06 PM
$ABCL clowns share price did not go up by 300% after phase 2 data to celebrate public offering dont be fgs....
0 · Reply
Rastafari
Rastafari Aug. 11 at 9:59 PM
$ABCL regarding the stock offering, note what happend to Cogent as an example: 2025 Cogent’s offering was priced at $9.00, with approximately $200M of gross proceeds. But instead of falling, the stock went: * July 8: $9.78 * July 9: $10.38 * July 10: $10.83 * July 11: $10.97 * July 16: $11.84 * July 17: $12.21 That’s approximately +24.8% in one week from the $9.78 pre-offering price. Today, they trade at $39! For those who are long, this is a non-event. The funds will help the company accelerate their go to market plan. In a week or two we will see a strong rebound. Expect a pullback this week. It will be interesting to see what the offer price will be!
2 · Reply
Latest News on ABCL
AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 2 hours ago

AbCellera announces $200M common stock, warrants offering


AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 9 hours ago

AbCellera price target raised to $30 from $12 at Truist


AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 1 day ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 1 day ago

AbCellera Biologics Transcript: Study result


AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 1 day ago

AbCellera Biologics Press release: Study result


AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 1 day ago

AbCellera Biologics Slides: Study result


AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 5 days ago

AbCellera price target raised to $9 from $8 at Stifel


AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026


AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 days ago

AbCellera Biologics Slides: Q2 2026


AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 days ago

AbCellera Biologics Earnings release: Q2 2026


AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 days ago

AbCellera Biologics Quarterly report: Q2 2026


AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 6 days ago

AbCellera Reports Q2 2026 Business Results


AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 5 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 5 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


raccoonblackbear
raccoonblackbear Aug. 11 at 10:35 PM
$ABCL loving these new bears who just came out of the woods and decided that crossing highways would be their new hobby. No one is a fan of the timing of the offering, but this will effectively shut anyone up who says ABCL will run out of cash before the completion of Phase 3. 2 steps backwards... 100 steps forward. My guess is the offering will be about a 10% discount from the time of the announcement... So $8.50-$9.00 becomes the new rock solid floor after the short attack. Let the bears think they have this one. Congrats longs. Y'all know who you are.
0 · Reply
PattyBergeron
PattyBergeron Aug. 11 at 10:33 PM
$ABCL im unphased. Smart business planning to preserve capital to advance the program. Offering announced but still flat on the day at the end of it.
0 · Reply
Titosimox
Titosimox Aug. 11 at 10:31 PM
$ABCL I am always astounded by the number of comments from would-be short-term traders who haven't grasped the first thing about investing and managing a company's growth. While fools stare at dung flies, investors gaze at the stars—and remain patient.
0 · Reply
PolarBear1
PolarBear1 Aug. 11 at 10:29 PM
$ABCL My guess is it’s already way oversubscribed (at or within 10% of market) and they take more than $200MM. Baker Brothers takes at least 33% (pre-funded warrants is one of their signatures) and one of the brothers (likely Felix) joins the Board post Issue. That would be fantastic news indeed. Then they’ll announce a major pharma development/marketing partnership for 635 just prior to JP Morgam Healthcare conference in SFO in mid January 2027. $15-$20 ps by then if so.
0 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 11 at 10:28 PM
$ABCL perspective: $200M for a $3B company
0 · Reply
SnoddyTradz
SnoddyTradz Aug. 11 at 10:22 PM
$ABCL If you’re still holding at this point! Stop Trading!🤣
0 · Reply
topstockalerts
topstockalerts Aug. 11 at 10:16 PM
AbCellera Biologics shares declined in after-hours trading Tuesday after the clinical-stage biotech announced a proposed $200M underwritten public offering of common stock. For certain investors, the company may offer pre-funded warrants to purchase common shares instead. All securities in the offering will be issued and sold by AbCellera. The company expects to use the net proceeds primarily to support continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635. Funds will also be used for working capital and other general corporate purposes, providing additional liquidity as AbCellera advances its drug candidates through clinical development. The proposed offering remains subject to market and other customary conditions, and AbCellera said there is no assurance that it will be completed, when it will close, or what its final size and terms will be. $ABCL
0 · Reply
SnoddyTradz
SnoddyTradz Aug. 11 at 10:11 PM
$ABCL This is so Cooked tomorrow! Stick a fork in it! It’s Done! 6.00 tomorrow!
1 · Reply
tradersunion353
tradersunion353 Aug. 11 at 10:06 PM
$ABCL clowns share price did not go up by 300% after phase 2 data to celebrate public offering dont be fgs....
0 · Reply
Rastafari
Rastafari Aug. 11 at 9:59 PM
$ABCL regarding the stock offering, note what happend to Cogent as an example: 2025 Cogent’s offering was priced at $9.00, with approximately $200M of gross proceeds. But instead of falling, the stock went: * July 8: $9.78 * July 9: $10.38 * July 10: $10.83 * July 11: $10.97 * July 16: $11.84 * July 17: $12.21 That’s approximately +24.8% in one week from the $9.78 pre-offering price. Today, they trade at $39! For those who are long, this is a non-event. The funds will help the company accelerate their go to market plan. In a week or two we will see a strong rebound. Expect a pullback this week. It will be interesting to see what the offer price will be!
2 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 11 at 9:57 PM
$ABCL positive: funding with purpose. negative: funding for survival. This is obviously 🚀🚀 funding!
0 · Reply
rickvug
rickvug Aug. 11 at 9:46 PM
$ABCL It will be interesting to see what price does tomorrow and then over the coming weeks. If AbCellera is to raise funds via dilution it is better to rip off the bandaid now. Get the clearing event out of the way early, no "will they, won't they" overhang. I like the stability these additional funds give the company and how it will allow them to re-invest. Even with the extra cash I'm still leary if AbCellera decides to go it on their own for Phase 3 vs. sell off 50% of the program to hand this off to a partner who has more experience in late stage trials and commercialization. Better to take the known cash to re-invest in the platform and other programs. Secure ongoing revenue streams before taking on Phase 3 testing on their own.
0 · Reply
Ckkung71
Ckkung71 Aug. 11 at 9:37 PM
$ABCL The golden goose wants to keep all future medicines fore them self. Now they soon have money to develop them self 💰
0 · Reply
TradeWinner
TradeWinner Aug. 11 at 9:32 PM
$ABCL hmmmm. Didn’t expect that. Hopefully favorable pricing.
0 · Reply
JennyRowes
JennyRowes Aug. 11 at 9:28 PM
$ABCL management kept strong balance sheet through biotech nuclear winter. No raises in over 6 years. Deal out big value inflection with 635. Raise 200M to fully fund a phase 3. Keep 100% ownership of program. Bring on new big investors. Dilution around 6%, about equal to the typical daily swing. i love it.
0 · Reply
tradersunion353
tradersunion353 Aug. 11 at 9:24 PM
$ABCL as usual clowns started celebrating about this share price drop after public offering never seem such fools married to a stock
1 · Reply
Kaykay610
Kaykay610 Aug. 11 at 9:19 PM
$ABCL let them cook ignore the noise, we are about eat
0 · Reply
SwingTrades1
SwingTrades1 Aug. 11 at 9:18 PM
$ABCL This is pretty cool. **$9$10 is starting to look like the Berlin Wall.** 😂
0 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 11 at 9:09 PM
$ABCL minor issue. Perhaps I can grab a few more in an early morning dip🚀🚀
1 · Reply
SwingTrades1
SwingTrades1 Aug. 11 at 9:05 PM
$ABCL Round 2. Round 1 was post-Q2. Maybe this time we can finally break through $10–12.
0 · Reply
hoggerj
hoggerj Aug. 11 at 9:04 PM
$ABCL bulls the offering is no surprise. We no longer need to listen to the rhetoric of running out of money. Small amount really relative to number of shares outstanding. This is enough money to advance thru phase 3 to commercialization while all the other programs advance.
1 · Reply
Bullock3000
Bullock3000 Aug. 11 at 8:57 PM
$ABCL I'm guessing they will sell those around $7.60.
2 · Reply